sibutramine has been researched along with Weight Gain in 31 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current trial investigated the effect of add-on treatment with sibutramine in schizophrenia outpatients who had gained more than 7% of weight during the course of treatment." | 9.19 | Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. ( Biedermann, F; Ebenbichler, CF; Fleischhacker, WW; Hofer, A; Kemmler, G; Lechleitner, M, 2014) |
| "Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation." | 9.14 | Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study. ( Clark, MM; Croghan, IT; Ebbert, JO; Hays, JT; Schroeder, DR; Sood, A, 2009) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 9.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 9.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 9.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, had been taking a stable dose of olanzapine for at least 4 months, and had a body mass index of >/=30 kg/m(2) or >/=27 kg/m(2) plus at least one cardiovascular risk factor." | 9.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 9.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 7.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| " She started sibutramine treatment and presented with amenogalactorrhea." | 7.77 | A case of sibutramine-induced hyperprolactinemia. ( da Costa Oliveira, M; Pereira-Lima, JF; Soares Leaes, CG, 2011) |
| "Sibutramine treatment decreased body weight gain by 12% without a significant overall change in daily food intake." | 7.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| " Single dosing with sibutramine (3." | 5.35 | Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. ( Blundell, JE; Rodgers, RJ; Tallett, AJ, 2009) |
| " The current trial investigated the effect of add-on treatment with sibutramine in schizophrenia outpatients who had gained more than 7% of weight during the course of treatment." | 5.19 | Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia. ( Biedermann, F; Ebenbichler, CF; Fleischhacker, WW; Hofer, A; Kemmler, G; Lechleitner, M, 2014) |
| "To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine." | 5.16 | Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. ( Brooke, A; Delafont, B; Elkhawad, M; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Tan, CY; Vidal-Puig, A; Virtue, S, 2012) |
| "Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation." | 5.14 | Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study. ( Clark, MM; Croghan, IT; Ebbert, JO; Hays, JT; Schroeder, DR; Sood, A, 2009) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects." | 5.12 | A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Nguyen, DD; Zhang, H, 2007) |
| "To describe the comparative efficacy of orlistat and sibutramine in an obesity management program, with specific attention to compliance and weight regains after noncompliance." | 5.12 | Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance. ( Baskal, N; Cesur, M; Cin, MO; Erdogan, MF; Gursoy, A, 2006) |
| "In this 24-week, open-label, flexible-dose, comparison trial, 46 outpatients with bipolar disorders who had a body mass index (BMI) > or =30 kg/m(2), or > or =27 kg/m(2) with obesity-related comorbidities, and psychotropic-associated weight gain were randomly assigned to receive sibutramine (n = 18; 5-15 mg/day) or topiramate (n = 28; 25-600 mg/day)." | 5.12 | A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. ( Altshuler, LL; Black, D; Denicoff, KD; Frye, MA; Hellemann, G; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, W; Post, RM; Suppes, T, 2007) |
| "Each subject had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder, had been taking a stable dose of olanzapine for at least 4 months, and had a body mass index of >/=30 kg/m(2) or >/=27 kg/m(2) plus at least one cardiovascular risk factor." | 5.11 | A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. ( Borba, CP; Cather, C; Copeland, PM; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC; Louie, PM; Nguyen, DD, 2005) |
| "After Sibutramine discontinuation patients had weight gain but they did not reach the baseline body weight." | 5.09 | Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. ( Berber, A; Cortinas, L; Fanghänel, G; Sánchez-Reyes, L, 2001) |
| "Topiramate (alone or associated with sibutramine) and orlistat (alone or in combination) promoted significant weight loss after 2 years of use in patients submitted to bariatric surgery with weight regain." | 4.31 | Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study. ( Boger, BS; Canuto, MC; Cercato, C; de Melo, ME; Mancini, MC; Noriega, PEP; Queiroz, NL; Stumpf, MAM, 2023) |
| "Orlistat and sibutramine had early effects on weight loss, not sustained over 3 years." | 3.81 | The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. ( Batterham, RL; Bhaskaran, K; Douglas, IJ; Smeeth, L, 2015) |
| " She started sibutramine treatment and presented with amenogalactorrhea." | 3.77 | A case of sibutramine-induced hyperprolactinemia. ( da Costa Oliveira, M; Pereira-Lima, JF; Soares Leaes, CG, 2011) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| " Sibutramine treatment did not affect the dietary behaviour of high-protein- or high-carbohydrate-fed rats, while it significantly attenuated the daily food intake and body weight gain rate in the high-fat group, at the dose of 10 mg/kg." | 3.74 | Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats. ( Couvari, E; Dontas, I; Galanopoulou, P; Liapi, C; Mavri, M; Perelas, A; Perrea, D; Stroubini, T; Trapali, M, 2008) |
| "Dexfenfluramine (DEX) and sibutramine (SIB) are effective antiobesity agents." | 3.73 | Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. ( Brune, ME; Bush, EN; Droz, BA; Fey, T; Jacobson, PB; Knourek-Segel, VE; Lin, E; Shapiro, R, 2006) |
| "Sibutramine treatment decreased body weight gain by 12% without a significant overall change in daily food intake." | 3.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| " Single dosing with sibutramine (3." | 1.35 | Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats. ( Blundell, JE; Rodgers, RJ; Tallett, AJ, 2009) |
| "Lean and obese Zucker rats were orally dosed with SR 141716 (3, 10, 30 mg/kg PO), sibutramine (5 mg/kg PO) or vehicle for one week." | 1.32 | Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. ( Dourish, CT; Kennett, GA; Vickers, SP; Webster, LJ; Wyatt, A, 2003) |
| "To determine the effect of acute and chronic administration of a new food intake-reducing compound (HMR1426) with novel mode of action (retardation of gastric emptying) on body weight development, food intake, and energy metabolism in rats." | 1.32 | The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats. ( Bickel, M; Geisen, K; Gossel, M; Jähne, G; Kampe, J; Klaus, S; Lang, HJ; Ortmann, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.90) | 18.2507 |
| 2000's | 20 (64.52) | 29.6817 |
| 2010's | 6 (19.35) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Boger, BS | 1 |
| Queiroz, NL | 1 |
| Noriega, PEP | 1 |
| Canuto, MC | 1 |
| Stumpf, MAM | 1 |
| Cercato, C | 1 |
| Mancini, MC | 1 |
| de Melo, ME | 1 |
| Biedermann, F | 1 |
| Fleischhacker, WW | 1 |
| Kemmler, G | 1 |
| Ebenbichler, CF | 1 |
| Lechleitner, M | 1 |
| Hofer, A | 1 |
| Douglas, IJ | 1 |
| Bhaskaran, K | 1 |
| Batterham, RL | 1 |
| Smeeth, L | 1 |
| Tallett, AJ | 2 |
| Blundell, JE | 2 |
| Rodgers, RJ | 2 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 1 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Sood, A | 1 |
| Ebbert, JO | 1 |
| Clark, MM | 1 |
| Croghan, IT | 1 |
| Schroeder, DR | 1 |
| Hays, JT | 1 |
| Kaplan, LM | 1 |
| Soares Leaes, CG | 1 |
| Pereira-Lima, JF | 1 |
| da Costa Oliveira, M | 1 |
| Napolitano, A | 1 |
| Miller, SR | 1 |
| Murgatroyd, PR | 1 |
| Delafont, B | 1 |
| Brooke, A | 1 |
| Elkhawad, M | 1 |
| Tan, CY | 1 |
| Virtue, S | 1 |
| Vidal-Puig, A | 1 |
| Nunez, DJ | 1 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Vickers, SP | 1 |
| Webster, LJ | 1 |
| Wyatt, A | 1 |
| Dourish, CT | 1 |
| Kennett, GA | 1 |
| Casado, A | 1 |
| Rodríguez, VM | 1 |
| Portillo, MP | 1 |
| Macarulla, MT | 1 |
| Abecia, LC | 1 |
| Echevarría, E | 1 |
| Casis, L | 1 |
| Matsumoto, K | 1 |
| Iijima, H | 1 |
| Ortmann, S | 1 |
| Kampe, J | 1 |
| Gossel, M | 1 |
| Bickel, M | 1 |
| Geisen, K | 1 |
| Jähne, G | 1 |
| Lang, HJ | 1 |
| Klaus, S | 1 |
| Henderson, DC | 2 |
| Copeland, PM | 2 |
| Daley, TB | 2 |
| Borba, CP | 2 |
| Cather, C | 2 |
| Nguyen, DD | 2 |
| Louie, PM | 1 |
| Evins, AE | 2 |
| Freudenreich, O | 2 |
| Hayden, D | 2 |
| Goff, DC | 2 |
| Bush, EN | 1 |
| Shapiro, R | 1 |
| Brune, ME | 1 |
| Knourek-Segel, VE | 1 |
| Droz, BA | 1 |
| Fey, T | 1 |
| Lin, E | 1 |
| Jacobson, PB | 1 |
| Alisky, JM | 1 |
| Fan, X | 1 |
| Zhang, H | 1 |
| Gursoy, A | 1 |
| Erdogan, MF | 1 |
| Cin, MO | 1 |
| Cesur, M | 1 |
| Baskal, N | 1 |
| McElroy, SL | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Suppes, T | 1 |
| Hellemann, G | 1 |
| Black, D | 1 |
| Mintz, J | 1 |
| Kupka, R | 1 |
| Nolen, W | 1 |
| Leverich, GS | 1 |
| Denicoff, KD | 1 |
| Post, RM | 1 |
| Keck, PE | 1 |
| Bahadori, B | 1 |
| Uitz, E | 1 |
| Tonninger-Bahadori, K | 1 |
| Moghadasian, MH | 1 |
| Baptista, T | 1 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Trapali, M | 1 |
| Liapi, C | 1 |
| Perelas, A | 1 |
| Perrea, D | 1 |
| Stroubini, T | 1 |
| Dontas, I | 1 |
| Couvari, E | 1 |
| Mavri, M | 1 |
| Galanopoulou, P | 1 |
| Day, C | 1 |
| Bailey, CJ | 1 |
| Maughan, KL | 1 |
| Lean, M | 1 |
| Greenberg, I | 1 |
| Chan, S | 1 |
| Blackburn, GL | 1 |
| Fanghänel, G | 1 |
| Cortinas, L | 1 |
| Sánchez-Reyes, L | 1 |
| Berber, A | 1 |
| Jakicic, JM | 1 |
| Clark, K | 1 |
| Coleman, E | 1 |
| Donnelly, JE | 1 |
| Foreyt, J | 1 |
| Melanson, E | 1 |
| Volek, J | 1 |
| Volpe, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Eat Well for Life: A Weight Loss Maintenance Study[NCT01849627] | 345 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | |||
| Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults[NCT01803737] | 26 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body weight will be measured on a digital scale to assess change in body weight over the 12-week intervention period. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kg (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -5.6 |
| Campaign Intervention (CI) | -3.1 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of carbohydrate intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.64 |
| Campaign Intervention (CI) | 0.90 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of fat intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | -3.26 |
| Campaign Intervention (CI) | -0.00 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of protein intake (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 0.73 |
| Campaign Intervention (CI) | 0.44 |
A questionnaire will be used to assess self-reported food intake. This will be used to estimate calories, dietary fat, protein, and carbohydrates consumed. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/day (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 474.8 |
| Campaign Intervention (CI) | 242.5 |
A questionnaire will be used to measure and quantify energy expenditure from physical activity. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | kcals/wk (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 983.3 |
| Campaign Intervention (CI) | 776.3 |
Self-efficacy for weight loss was assessed at week 0 and 12 using a 20-item Weight Efficacy Lifestyle Questionnaire (WEL). The total score ranges from 0-180. Higher values represent greater beliefs toward the completion of weight management behaviors. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 28.3 |
| Campaign Intervention (CI) | 16.3 |
The frequency that participants engaged in the self-monitoring of dietary intake and physical activity was assessed at week 12. The diaries were completed weekly throughout the study. (NCT01803737)
Timeframe: Week 0 and 12
| Intervention | percentage of diaries completed (Mean) |
|---|---|
| Standard Behavioral Weight Loss Intervention (SBWL) | 91.6 |
| Campaign Intervention (CI) | 60.1 |
At week 12, participants completed the 13-item TSRQ to assess motivation to continue to participate in the program if given the opportunity. The TSRQ represents participants' reasons for continuing participation in a weight loss program via participants' endorsement of statements of autonomous and controlled motivation. Responses were given using a 7-point Likert scale (1 = not at all true to 7 = very true). The responses on the autonomous items (5) and controlled items (8) were averaged. (NCT01803737)
Timeframe: Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Autonomous Motivation | Controlled Motivation | |
| Campaign Intervention (CI) | 5.3 | 2.9 |
| Standard Behavioral Weight Loss Intervention (SBWL) | 6.3 | 2.9 |
6 reviews available for sibutramine and Weight Gain
| Article | Year |
|---|---|
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
Cutting fat absorption to halt weight gain.
Topics: Anti-Obesity Agents; Cyclobutanes; Diet, Fat-Restricted; Family Practice; Humans; Intestinal Absorpt | 1998 |
Nonpharmacologic and pharmacologic management of weight gain.
Topics: Anti-Obesity Agents; Appetite Depressants; Behavior Therapy; Cyclobutanes; Diet, Reducing; Energy In | 1999 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults.
Topics: Adult; Body Mass Index; Cyclobutanes; Diet Therapy; Dietary Fats; Energy Intake; Exercise Therapy; H | 2001 |
9 trials available for sibutramine and Weight Gain
| Article | Year |
|---|---|
Sibutramine in the treatment of antipsychotic-induced weight gain: a pilot study in patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Appetite Depressants; Cyclobutanes; Female; Humans; Male; Middle | 2014 |
Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study.
Topics: Adult; Appetite Depressants; Benzazepines; Cyclobutanes; Drug Therapy, Combination; Female; Humans; | 2009 |
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.
Topics: Absorptiometry, Photon; Adult; Appetite Depressants; Body Composition; Body Weight; Calorimetry, Ind | 2012 |
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Behavior Therapy; Benzodiazepines; Combined Modal | 2005 |
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Topics: Adult; Anthropometry; Antipsychotic Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Bo | 2007 |
Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Diet, Red | 2006 |
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Appetite Depressants; Bipolar D | 2007 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over.
Topics: Adolescent; Adult; Aged; Anthropometry; Appetite Depressants; Body Mass Index; Body Weight; Cross-Ov | 2001 |
16 other studies available for sibutramine and Weight Gain
| Article | Year |
|---|---|
Treatment with Antiobesity Drugs in Weight Regain After Bariatric Surgery: a Retrospective Cohort Study.
Topics: Aged; Anti-Obesity Agents; Bariatric Surgery; Female; Humans; Male; Middle Aged; Obesity, Morbid; Or | 2023 |
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Case-Control Studies; Cyclobutane | 2015 |
Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
Topics: Animals; Anorexia; Appetite Depressants; Cyclobutanes; Dose-Response Relationship, Drug; Eating; Fee | 2009 |
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |
Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.
Topics: Animals; Appetite; Cyclobutanes; Drug Administration Schedule; Drug Therapy, Combination; Male; Pipe | 2010 |
A case of sibutramine-induced hyperprolactinemia.
Topics: Adult; Amenorrhea; Appetite Depressants; Cyclobutanes; Diagnosis, Differential; Female; Galactorrhea | 2011 |
Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.
Topics: Animals; Appetite Depressants; Cannabinoids; Cyclobutanes; Dose-Response Relationship, Drug; Eating; | 2003 |
Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins.
Topics: Adipose Tissue; Animals; Appetite Depressants; Body Composition; Carrier Proteins; Cyclobutanes; Dri | 2003 |
Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice.
Topics: Animals; Appetite Depressants; Cyclobutanes; Disease Models, Animal; Feeding Behavior; Female; Hyper | 2003 |
The novel antiobesic HMR1426 reduces food intake without affecting energy expenditure in rats.
Topics: Animals; Anti-Obesity Agents; Cyclobutanes; Eating; Energy Metabolism; Heterocyclic Compounds, 3-Rin | 2004 |
Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Dexfenfluramine; Diet, Fat-Restricted; Ghre | 2006 |
Phentermine, sibutramine and metformin could be used for the prevention and treatment of steroid-induced weight gain.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Humans; Hypoglycemic Agents; Metformin; Phent | 2007 |
Successful treatment of a morbidly obese and growth-retarded adolescent with Williams-Beuren Syndrome by combining the medication of growth hormone and sibutramine.
Topics: Adolescent; Appetite Depressants; Body Composition; Body Mass Index; Body Weight; Cyclobutanes; Huma | 2008 |
Effect of isocaloric diets and sibutramine on food intake, body mass variation and serum TNF-alpha levels in rats.
Topics: Animals; Appetite Depressants; Body Weight; Cyclobutanes; Diet; Dietary Carbohydrates; Dietary Fats; | 2008 |
Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Topics: Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Fatty Acids, Nonester | 1998 |
Does sibutramine keep the weight off?
Topics: Cyclobutanes; Diet, Reducing; Double-Blind Method; Energy Intake; Humans; Obesity; Randomized Contro | 1999 |